Advertisement

ASO Author Reflections: Prolonged Immunoparalysis of NK Cells After Surgery

  • Leonard Angka
  • Rebecca C. Auer
ASO Author Reflections
  • 18 Downloads

Notes

Disclosures

Study reagents (NK-Vue™) provided by ATGen Canada Inc.

References

  1. 1.
    Imai K, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000;356(9244):1795–9.CrossRefGoogle Scholar
  2. 2.
    Tartter PI, et al. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg. 1987;122(11):1264–8.CrossRefGoogle Scholar
  3. 3.
    Horowitz M, et al. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol. 2015;12(4):213–26.CrossRefGoogle Scholar
  4. 4.
    Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10(8):972–92.CrossRefGoogle Scholar
  5. 5.
    Tai LH, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013;73(1):97–107.CrossRefGoogle Scholar
  6. 6.
    Angka L, et al. Dysfunctional natural killer cells in the aftermath of cancer surgery. Int J Mol Sci. 2017;18(8):1787.CrossRefGoogle Scholar
  7. 7.
    Angka L, Martel AB, Kilgour M, et al. Natural killer cell IFNγ secretion is profoundly suppressed following colorectal cancer surgery. Ann Surg Oncol. 2018.  https://doi.org/10.1245/s10434-018-6691-3 CrossRefPubMedGoogle Scholar
  8. 8.
    Cooper MA, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97(10):3146–51.CrossRefGoogle Scholar
  9. 9.
    Michel T, et al. Human CD56bright NK cells: an update. J Immunol. 2016;196(7):2923–31.CrossRefGoogle Scholar
  10. 10.
    Derby EG, et al. Correlation of human CD56 + cell cytotoxicity and IFN-gamma production. Cytokine 2001;13(2):85–90.CrossRefGoogle Scholar
  11. 11.
    Tohme S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res. 2017;77(7):1548–1552.CrossRefGoogle Scholar
  12. 12.
    Nichols PH, et al. Peri-operative modulation of cellular immunity in patients with colorectal cancer. Clin Exp Immunol. 1993;94(1):4–10.CrossRefGoogle Scholar
  13. 13.
    Klatte T, et al. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Br J Cancer. 2006;95(9):1167–73.CrossRefGoogle Scholar
  14. 14.
    Tai LH, et al. Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of natural killer cell cytotoxicity. Oncoimmunology 2018;7(6):e1431082.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Centre for Innovative Cancer ResearchOttawa Hospital Research InstituteOttawaCanada
  2. 2.Department of Microbiology and ImmunologyUniversity of OttawaOttawaCanada
  3. 3.Division of General Surgery, Department of SurgeryUniversity of OttawaOttawaCanada

Personalised recommendations